


# ENTHUSE

## A Unique Opportunity to be Part of an International Clinical Trial Programme in M0 Castrate-resistant Prostate Cancer

### Ongoing Phase III Clinical Trial Programme in Hormone-resistant Prostate Cancer Evaluating Specific Endothelin A Receptor Antagonism



\*Patients may also receive standard prostate cancer therapies

### ENTHUSE (MO) – Study 15 (D4320C00015)

Randomised, Double-blind, Multicenter Phase III Study in Patients with Non-metastatic, Hormone-resistant Prostate Cancer

## CURRENTLY RECRUITING

### Target patient population (n=1500)

Patients with non-metastatic, hormone-resistant prostate cancer with rising serum prostate-specific antigen (PSA) levels despite medical or surgical castration

- Purpose: to assess the efficacy and safety of Zibotentan (ZD4054) in improving overall survival and progression-free survival
- Primary endpoints: overall survival and progression-free survival
- For more information, please visit [www.clinicaltrials.gov](http://www.clinicaltrials.gov) and [www.astrazenecaclinicaltrials.com](http://www.astrazenecaclinicaltrials.com)

Key Inclusion Criteria	Key Exclusion Criteria
<ul style="list-style-type: none"><li>■ Male aged 18 years and above</li><li>■ Adenocarcinoma of the prostate</li><li>■ No evidence of metastatic disease. Pelvic lymph node involvement is acceptable</li></ul>	<ul style="list-style-type: none"><li>■ Current use of opiate medication</li><li>■ Prior cytotoxic chemotherapy for the treatment of recurrent prostate cancer. Prior targeted cancer therapies are allowed if taken during a clinical trial</li></ul>

This information is intended for clinical investigators and other interested physicians who may wish to enroll or refer patients into this study. If you are interested please contact:

ENTHUSE.Programme@astrazeneca.com or Isabella Ruocco on +1 514 907 2020

Zibotentan (ZD4054) is an investigational compound

**AstraZeneca Contact Information:**  
ENTHUSE.Programme@astrazeneca.com

AstraZeneca 